TSXV - Delayed Quote CAD

NervGen Pharma Corp. (NGEN.V)

3.5400

-0.0500

(-1.39%)

At close: May 9 at 3:59:29 PM EDT

NervGen Pharma Announces Results of Annual General Meeting of Shareholders

All resolutions submitted for approval were passed by shareholdersVancouver, British Columbia--(Newsfile Corp. - May 7, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, announces the results of its Annual General Meeting of Shareholders ("AGM") held on May 6, 2025.The company reports that at the AGM the shareholders re-elected Brian Bayley, Harold Punnett, Randall Kaye, Krista McKerracher, Glenn Ives

Newsfile 3 days ago

NGENF
TSX Penny Stock Insights For May 2025

As the Canadian market navigates a complex landscape marked by trade developments and economic adjustments, the TSX has shown resilience, bolstered by strong performances in sectors like materials. In this context, investors might find value in exploring penny stocks—smaller or newer companies that can offer unique opportunities despite their somewhat outdated label. By focusing on those with robust financials and clear growth potential, these stocks may present compelling prospects for those...

Simply Wall St. 8 days ago

QYOUF

NGENF

HAIVF
NervGen Pharma to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

Vancouver, British Columbia--(Newsfile Corp. - April 21, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto, ON. Mike Kelly, President & CEO, is scheduled to present at the conference on Monday, May 5, 2025, at 10:00 a.m. EDT. Members of management will be available for one-on-one investor meeting

Newsfile 19 days ago

NGENF
NervGen Provides Quarterly "At-The-Market" Equity Program Update

Vancouver, British Columbia--(Newsfile Corp. - April 9, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today provided a quarterly update with respect to the Company's previously announced at-the-market equity program (the "ATM Program") launched on December 19, 2024. The ATM Program allows the Company to issue and sell common shares in the capital of the Company (the "C

Newsfile last month

NGENF
NervGen Pharma Reports 2024 Year-End Financial Results and Provides Business Updates

Completed enrollment in the chronic cohort and commenced enrollment in the subacute cohort of its Phase 1b/2a clinical trial for lead drug candidate, NVG-291, in spinal cord injury (SCI)Initiated an expanded access protocol for NVG-291 for individuals with SCI who have participated in a NervGen clinical trial and meet specific eligibility criteriaPipeline candidate NVG-300 showing promising activity in preclinical models of ischemic stroke and SCIVancouver, British Columbia--(Newsfile Corp. - Ap

Newsfile last month

NGENF
TSX Penny Stocks Under CA$900M Market Cap: 3 Intriguing Picks

As newly announced tariffs and inflation concerns continue to drive market volatility, Canadian investors are navigating a landscape where economic growth could face headwinds. Amidst these challenges, penny stocks—often representing smaller or newer companies—remain an intriguing area for potential investment. While the term "penny stocks" may seem outdated, these securities can offer opportunities for growth at lower price points when backed by strong financials and solid fundamentals.

Simply Wall St. last month

RTTGF

DSVSF

NGENF
NervGen Initiates Expanded Access Policy

The U.S. Food and Drug Administration (FDA) informed the company that an expanded access protocol for NVG-291 may proceedThis news release constitutes a "designated news release" for the purposes of NervGen's prospectus supplement dated December 19, 2024 to its short form base shelf prospectus dated November 25, 2024.Vancouver, British Columbia--(Newsfile Corp. - March 31, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorest

Newsfile last month

NGENF
NervGen Pharma to Host Virtual Investor Event

Key opinion leaders and company management will discuss the current spinal cord injury treatment landscape and NervGen's Phase 1b/2a clinical trial evaluating NVG-291 in individuals with spinal cord injuryVANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that it will host a virtual investor event on Wednesday, April 9, 2025, at 1

GlobeNewswire last month

NGENF
NervGen Pharma Grants Stock Options

Vancouver, British Columbia--(Newsfile Corp. - March 14, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that it has granted 545,000 incentive stock options (the "Options") to employees and consultants of the company, including 100,000 to the company's officers and 15,000 to consultants providing investor relations services. The Options are exercisable at a price of $2.74 per share.

Newsfile last month

NGENF
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum, held March 13th are now available for online viewing. REGISTER NOW AT: https://bit.ly/3DIWqav The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download

GlobeNewswire last month

PDSB

TELIF

BPTSY
Life Sciences Investor Forum Agenda Announced for March 13th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum March 13th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/4hnure6 It is recommended that inve

GlobeNewswire last month

NGENF

BPTSY

HMTXF
NervGen Pharma to Present at the Virtual Life Science Investor Forum

Vancouver, British Columbia--(Newsfile Corp. - March 5, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that Mr. Mike Kelly, President & CEO, will be presenting at the Virtual Life Sciences Investor Forum hosted by OTC Markets Group and VirtualInvestorConferences.com, on Thursday, March 13, 2025, at 12:00 p.m. EDT. Members of management will be available for virtual one-on-one invest

Newsfile 2 months ago

NGENF
NervGen Completes Dosing of First Subject in Subacute Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Vancouver, British Columbia--(Newsfile Corp. - February 6, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that the first subject has been enrolled and dosed in the subacute cohort of its Phase 1b/2a proof-of-concept, double-blind, randomized placebo-controlled clinical trial (NCT05965700) evaluating its lead candidate, NVG-291, in individuals with spinal cord injury (SCI). The compa

Newsfile 3 months ago

NGENF
NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Vancouver, Canada--(Newsfile Corp. - January 29, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that Mr. Mike Kelly, President & CEO, will be participating in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025, at 8:40 a.m. EST. The conference is being held virtually February 11-12, 2025. Members of management will be ava

Newsfile 3 months ago

NGENF
NervGen Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Topline data from the chronic cohort is expected in Q2 2025Institutional Review Board (IRB) protocol amendment changes approved, and screening has been initiated for subacute cohortThis news release constitutes a "designated news release" for the purposes of NervGen's prospectus supplement dated December 19, 2024 to its short form base shelf prospectus dated November 25, 2024.Vancouver, British Columbia--(Newsfile Corp. - January 2, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a cli

Newsfile 4 months ago

NGENF
NervGen Announces "At-The-Market" Equity Program

Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, is pleased to announce that it has established an at-the-market equity program (the "ATM Program") that allows the Company to issue and sell common shares in the capital of the Company (the "Common Shares") to the public from time to time through Stifel Nicolaus Ca

Newsfile 4 months ago

NGENF
NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates

Target enrollment in the chronic cohort of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury (SCI) is approaching completionNVG-300 preclinical test-of-concept studies in ischemic stroke, amyotrophic lateral sclerosis (ALS) and SCI underwayVancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, reported its financial

Newsfile 5 months ago

NGENF
NervGen Pharma to Present at the Stifel 2024 Healthcare Conference

Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, announced today that Mr. Mike Kelly, President & CEO, will be participating in a fireside chat at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024, at 10:20 a.m. EST. Members of management will be available for one-on-one investor meetings during the conference.The conference

Newsfile 5 months ago

NGENF
NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Target enrollment in the chronic cohort close to completionVancouver, British Columbia--(Newsfile Corp. - September 30, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that target enrollment of the chronic cohort in its Phase 1b/2a proof-of-concept, double-blind, randomized placebo-controlled clinical trial (NCT05965700) for its proprietary investiga

Newsfile 7 months ago

NGENF
NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury

Vancouver, British Columbia--(Newsfile Corp. - September 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., NervGen's Chief Medical Officer, will give an oral presentation at the Unite 2 Fight Paralysis (U2FP) 19th Annual Science & Advocacy Symposium, taking place on September 27-28, 2024, in Atlanta, Georgia. Dr. Mikol

Newsfile 7 months ago

NGENF

Performance Overview

Return	NGEN.V	S&P/TSX Composite index (^GSPTSE)
YTD	+15.12%	+2.99%
1-Year	+75.25%	+13.33%
3-Year	+68.57%	+26.79%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

NervGen Pharma Corp. (NGEN.V)

NervGen Pharma Announces Results of Annual General Meeting of Shareholders

TSX Penny Stock Insights For May 2025

NervGen Pharma to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

NervGen Provides Quarterly "At-The-Market" Equity Program Update

NervGen Pharma Reports 2024 Year-End Financial Results and Provides Business Updates

TSX Penny Stocks Under CA$900M Market Cap: 3 Intriguing Picks

NervGen Initiates Expanded Access Policy

NervGen Pharma to Host Virtual Investor Event

NervGen Pharma Grants Stock Options

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Life Sciences Investor Forum Agenda Announced for March 13th

NervGen Pharma to Present at the Virtual Life Science Investor Forum

NervGen Completes Dosing of First Subject in Subacute Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

NervGen Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

NervGen Announces "At-The-Market" Equity Program

NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates

NervGen Pharma to Present at the Stifel 2024 Healthcare Conference

NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury

Performance Overview